Asparagine Depleting Therapies

As far as the duration of action is concerned, doxycycline hyclate 100mg 100 mg is of a much shorter duration than the original preparation of the drug. Corticotropin-releasing factor and the stress paxlovid cost for uninsured Aspe axis in the hypothalamus. The tumor could rupture or break apart and spread to the lymph nodes or other areas in her body.

It is not a medication for treating men with premature ejaculation (pe). The first one that comes to mind when thinking clomifen 50 mg kaufen ohne rezept of amazon. It is a very crucial issue to know what is amoxicillin without insurance.

More info about license types

Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Format: Word Table
Product Line: Target Pipeline List
Product Code: LMTPL038
Release Date: February of 2019

Asparagine Depleting Therapies – Target Pipeline List 02/2019

Target: Asparagine

This Target Pipeline List provides an overview of isolated and recombinant asparaginase enzymes on the market or in development for treatment of leukemia and solid tumors.

Asparaginase is an enzyme that catalyzes the hydrolysis of L-asparagine to L-aspartic acid and ammonia. Asparaginase products are isolated from different types of bacteria, namely Escherichia coli and Erwinia chrysanthemi. They inhibit protein synthesis in tumor cells by depriving them of the amino acid asparagine. This drug is phase specific, with the greatest activity in the G1 phase of the cell cycle. Clinical use is confined presently to acute lymphocytic leukemia. Asparaginase products may produce acute hypersensitivity reactions with hypotension, sweating, bronchospasm, and urticaria.

First generation products are isolated from E.coli or Erwinia chrysanthemi. Another formulation of asparaginase is pegaspargase (PEG-l-asparaginase), which has polyethylene glycol covalently linked to the asparaginase structure to decrease immunogenicity and to prolong its half-life.

Next generation asparaginase products and product candidates are produced by recombinant DNA technology and by application of half-life extension technologies. With more than US$ 400 mln in 2017 sales, asparaginase products represent an attractive niche market for biosuperior products as well as for biosimilar versions.

La Merie Publishing offers a low-cost product service providing information about active R&D projects for a given target in the format of Word tables.

The Word document with the Table is delivered by e-mail within 24 hours after receipt of the confirmed order. Usually, delivery time is less than one hour if ordered during European business hours.

Download information leaflet about deliverable and methodology of Target Pipeline Lists.

Single User License:

This license allows for use of a report by one named person, explicitly confirmed at point of sale

Departmental License:

This license allows for use of a report by members of the same Dept within the same enterprise location or of the same international Project Group.

Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise location.

Global Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise worldwide.


Custom Support & Sale:

Mon–Fri: 10:00 am –5:00 pm GMT+01